Presentations at EHA highlight gene therapy approaches to beta-thalassemia, sickle cell disease

Phase III data on bluebird bio’s Zynteglo, as well as Vertex and CRISPR Therapeutics’ CTX001, showed patients achieving transfusion independence via two gene therapy approaches.

Leave a Reply